COVID-19 Update | September 25, 2020
September 25, 2020
The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of September 25, 2020. Notable advancements include:
- Johnson & Johnson has entered the final stage of testing for its experimental COVID-19 vaccine, enrolling 60,000 volunteers in a landmark study.
- The U.S. Food and Drug Administration issued an emergency use authorization for the first antibody point-of-care test for COVID-19.
- Lumen Bioscience was awarded a $4 million grant by the U.S. Army Medical Research and Development Command to develop a biologic drug to treat gastrointestinal (GI) infection in COVID-19 patients.
- Merck, advancing single-dose and oral coronavirus vaccines, could still make Warp Speed: Bloomberg
FiercePharma – September 25, 2020
Merck & Co. is testing a vaccine that could be given orally, which would “help lower the barrier to vaccination should it be effective,” Merck R&D chief Roger Perlmutter said.
- Lumen Bioscience Receives $4 Million Grant to Develop COVID-19 GI Therapies
BioSpace – September 24, 2020
Seattle-based Lumen Bioscience was awarded a $4 million grant by the U.S. Army Medical Research and Development Command, operating via the Medical Technology Enterprise Consortium, to develop a rapid, scalable and inexpensive biologic drug to treat gastrointestinal (GI) infection in COVID-19 patients.
- Johnson &Johnson just launched a pivotal 60,000-person COVID-19 vaccine trial, and we could learn if the shot works by the end of 2020
Business Insider – September 23, 2020
Johnson & Johnson started giving its experimental COVID-19 vaccine to a 60,000 person group of volunteers, marking the final stage of testing for the shot.
- FDA Authorizes First Point-of-Care Antibody Test for COVID-19
FDA.gov – September 23, 2020
Today, the U.S. Food and Drug Administration issued an emergency use authorization for the first antibody point-of-care test for COVID-19.
- Possible virus vulnerability discovered; about 20% of people with COVID-19 remain asymptomatic
Reuters – September 23, 2020
Most people infected with the COVID-19 will have symptoms, according to researchers who reviewed data from nearly 80 studies of individuals with positive PCR tests for COVID-19 and overall, just 20% remained asymptomatic.
- AstraZeneca COVID-19 vaccine trial remains on hold in the U.S., HHS chief Azar says
CNBC – September 23, 2020
AstraZeneca’s late-stage COVID-19 vaccine trial in the U.S. remains on hold as federal investigators seek “answers to important questions” over its safety for patients, Health and Human Services Secretary Alex Azar told CNBC.
- Pfizer Is On Track to Be First to Find Out If Its COVID-19 Vaccine Works
Bloomberg – September 22, 2020
The COVID-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals.
- Eli Lilly CEO: Speed and industry cooperation are aiding COVID-19 treatment development
CNBC – September 21, 2020
Eli Lilly CEO Dave Ricks told CNBC the pharmaceutical industry’s pursuit of treatments and vaccines for the COVID-19 pandemic has been defined by two qualities: speed and cooperation.
Rely on California Biotechnology Foundation to monitor breaking news and provide updates on the latest advancements in COVID-19 diagnostics, vaccines and treatments.
Stay informed on the latest news and trends on the economic and health benefits of this industry by visiting the new CABiotech.org
If you have any questions about informational briefings contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or email@example.com.